Peptide Guides
Important
Neither BPC-157 nor TB-500 is an approved medicine in any country. Neither holds a licence from the MHRA in the United Kingdom, the EMA in Europe, or the FDA in the United States. This guide compares the two compounds' research records. It is not medical advice, and nothing within it constitutes a recommendation to use either compound. Products supplied through this site are intended for laboratory research use only.
Quick answer
- No, BPC-157 and TB-500 are not the same thing. They are different compounds with different origins, sizes and proposed mechanisms.
- Neither has demonstrated any effect in a full, published, controlled human trial, so "which is better" has no evidence-based answer.
- In the only direct controlled comparison, a 2026 rat tendon study, the clearest statistically significant improvements were in the TB-500 group, and combining the two added nothing.
- Both are prohibited in sport at all times, under different WADA categories.
BPC-157 vs TB-500: Side-by-Side Comparison
| BPC-157 | TB-500 | |
|---|---|---|
| What it is | A lab-made peptide of 15 amino acids copied from a section of a protein in human gastric juice | A product name for a lab-made copy of a small section (7 of 43 amino acids) of thymosin beta-4, a natural 43-amino-acid peptide |
| Where the name came from | "Body Protection Compound", from academic research in Croatia | A veterinary preparation, known first through horse-racing doping cases |
| Proposed mechanism | Signalling effects on blood vessel growth and tissue repair pathways, described in animal studies | Helping cells move and rebuild, the job of its parent protein, described in animal and cell studies |
| Animal evidence | Extensive, across many rodent injury models | Extensive for the parent protein; a small but growing record for the fragment itself |
| Published controlled human trials | None with full published results; earlier controlled trials exist only as conference abstracts | None for the fragment as sold; the parent protein has been through Phase 2 and 3 pharmaceutical trials without approval |
| Ongoing human research | A Phase 1 rotator cuff trial registered, due to start in 2027 | None; the FDA's 2026 review identified no human exposure data |
| WADA status | Prohibited at all times, named under S0 | Prohibited at all times, named under S2.3 |
| UK status | Lawful to supply for laboratory research; not a licensed medicine | Same |
What Are BPC-157 and TB-500?
BPC-157 is a lab-made peptide, a short chain of fifteen amino acids copied from a protein found naturally in the stomach. It does not exist in nature on its own and is made in a laboratory. The complete BPC-157 guide starts from the beginning if the compound is new to you.
TB-500 is a product name rather than a molecule name. The preparation it originally described contains a lab-made copy of a small section of thymosin beta-4, a natural 43-amino-acid peptide the body uses in healing, with one small chemical change.1 What TB-500 is explains this in full. The difference matters, because most "TB-500 research" is really research on the full-length peptide.
How Their Proposed Mechanisms Differ
The two compounds are usually presented as complementary. BPC-157 is described in animal research as influencing signalling pathways involved in blood vessel growth and tissue repair. TB-500 is a short fragment of thymosin beta-4, and most of the effects attributed to it are carried over from the full-length peptide's role in helping cells move and rebuild, not demonstrated for the fragment itself. Both descriptions come from animal and cell research, and both describe proposed mechanisms rather than demonstrated human effects. A mechanism is a hypothesis about how something might work, not evidence that it does, and the long history of animal versus human peptide research shows why mechanisms that hold up in rodents so often fail to transfer.
BPC-157 vs TB-500: Human and Animal Evidence
BPC-157's human record consists of three small uncontrolled reports from a single clinic, two earlier placebo-controlled trials reported only as conference abstracts, and registered trials without results, including a Phase 1 rotator cuff trial due to start in 2027. Every study and registered trial is catalogued in our record of BPC-157 clinical trials and human studies.
TB-500's human record is simpler: there is none. When the FDA reviewed the compound in July 2026, it stated that it had not identified human exposure data for products containing the TB-500 fragment.2 The trials people point to when calling TB-500 "clinically proven" actually tested full-length thymosin beta-4, a different molecule. Those trials ran for around twenty years, across wounds, eyes and the heart. None led to an approved medicine, and several programmes were stopped.3,4
A 2026 scoping review in the American Journal of Sports Medicine assessed both compounds for musculoskeletal use and reached the same conclusion for each: promising animal findings, human evidence lacking, claimed benefits unsubstantiated by current human trials.5
The Direct BPC-157 vs TB-500 Study
A single controlled study has compared the two compounds directly, and it was published in 2026. Researchers cut and repaired the Achilles tendons of 32 rats and treated groups with BPC-157, TB-500, both together, or nothing, for four weeks.6
The authors reported three things. TB-500 produced stronger healed tendons and better tissue scores than no treatment. BPC-157's improvements were smaller and did not reach statistical significance overall. And combining the two added no benefit over either compound alone.
That is one small study, in rats, at one time point, and it establishes nothing about humans. It is quoted here because it is the entire head-to-head literature, and because a rat study is not a reason to conclude anything about which compound "wins".
UK Legal and WADA Status
In sport, both compounds are banned at all times, in and out of competition. They sit under different parts of the WADA Prohibited List: BPC-157 is named under S0 (non-approved substances), while TB-500 is named under S2.3 (growth factors) as a derivative of thymosin beta-4.7 The category difference has no practical consequence for a tested athlete; both produce violations. Detection methods are published for both.
In the UK, the two occupy the same position: neither is listed as a controlled drug, and neither holds a marketing authorisation, so nothing containing them can be sold as a medicine. Genuine laboratory research products may fall outside medicines regulation, though classification ultimately depends on how a product is presented and intended to be used. The detail for each sits in TB-500 in the UK and BPC-157's UK legal status.
Is TB-500 Better Than BPC-157?
The question assumes evidence that does not exist. Neither compound has a full published controlled human trial showing it does anything, so there is no human basis for ranking them. In animals the records differ in shape rather than quality. BPC-157 has a broader rodent literature across injury types. Much of the larger preclinical record associated with TB-500 actually concerns full-length thymosin beta-4, which is deepest in wound and cardiac models. The one direct comparison favoured TB-500 on some tendon measures in rats. For a researcher, the better compound is simply the one that matches the research question, not the one with the bigger reputation.
Why Are BPC-157 and TB-500 Combined?
The two are marketed together as the "Wolverine Stack", on the theory that different mechanisms must add up. The one controlled test of that idea, in the rat tendon study above, found the combination performed no better than either compound alone.6 What the Wolverine Stack is covers the name, the claims and the evidence.
Common questions
Is TB-500 better than BPC-157?
No human study has compared them, and neither has controlled human evidence of any benefit, so no ranking is possible. The single animal comparison, in rat tendons, reported better results for TB-500 on some measures and no advantage from combining them.6
Can BPC-157 and TB-500 be used together?
They are sold together for research, and the combination is marketed as the Wolverine Stack. Whether combining them achieves anything is untested in humans, and the one controlled animal study found no additive effect.6 The Wolverine Stack guide goes through this in detail.
Are BPC-157 and TB-500 the same thing?
No. They are unrelated molecules: one comes from a protein in stomach fluid, the other from a healing-associated peptide found throughout the body. They are grouped together by marketing, not by chemistry.
Are they legal, and are they banned in sport?
Neither is a controlled drug in the UK and neither is a licensed medicine; both are supplied as laboratory research compounds. Both are prohibited in sport at all times under the WADA list.7
Research Specifications
View the current BPC-157 research specification, TB-500 research specification, or the combined BPC-157 + TB-500 research bundle. Each is freeze-dried powder, purity-tested by HPLC with a dated certificate of analysis per batch. We publish what each batch contains and make no claims about what either compound does.
Supplied for laboratory research use only. Not for human consumption.
References
- Esposito S, Deventer K, Goeman J, Van der Eycken J, Van Eenoo P. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal. 2012;4(9):733-8. DOI
- US Food and Drug Administration. Pharmacy Compounding Advisory Committee Briefing Document: TB-500. July 2026. FDA briefing document
- Sosne G, Kleinman HK, Springs C, et al. 0.1% RGN-259 (Thymosin ß4) ophthalmic solution promotes healing and improves comfort in neurotrophic keratopathy patients in a randomized, placebo-controlled, double-masked Phase III clinical trial. Int J Mol Sci. 2022;24(1):554. DOI
- Kruoch Z, Choo AY, Kemp A, et al. Medical and surgical interventions for neurotrophic keratopathy. Cochrane Database Syst Rev. 2025;12:CD015723. DOI
- Tewari K, Liu TP, Im C, et al. Peptide supplements and their therapeutic applications in sports medicine. Am J Sports Med. 2026. DOI
- Biçer O, Adanir O, Güleryüz Y, et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: a histopathological and biomechanical study. Jt Dis Relat Surg. 2026;37(3):822-837. DOI
- World Anti-Doping Agency. Prohibited List 2026, effective 1 January 2026, categories S0 and S2.3. WADA